German pharmaceuticals giant Bayer, maker of Aspirin, on Wednesday named Werner Baumann as its new chief executive to replace Marijn Dekkers, who is stepping down at the end of April.
Feb 24, 2016
0
0
Federal health regulators are reviewing the safety of an implantable contraception device after receiving reports of unusual side effects from patients, including fatigue, depression and weight gain.
Jun 25, 2015
0
23
German pharmaceuticals and chemicals giant Bayer said Wednesday it has agreed to sell its diabetes care business to Panasonic Healthcare Holdings for 1.022 billion euros ($1.2 billion).
Jun 10, 2015
0
15
In a win for consumers, the California Supreme Court ruled Thursday that settlement agreements between pharmaceutical companies that keep cheaper, generic drugs off the market may be illegal if they include excessive cash ...
May 7, 2015
0
10
(HealthDay)—Bayer's contraceptive implant Essure can cause serious complications and should be taken off the market, says a citizen's petition filed with the U.S. Food and Drug Administration.
May 5, 2015
0
54
When cancer patients take part in a clinical trial to develop new therapies, they and their physicians want to know how they will feel and function during treatment. A new collaboration between Bayer and The University of ...
Jan 23, 2015
0
13
Drugmaker Merck said Wednesday that it completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 ...
Oct 1, 2014
0
0
The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.
Sep 12, 2014
1
0
Germany's Bayer plans to buy U.S.-based Merck & Co.'s consumer health business, creating a combined medicine cabinet of household names from Bayer's aspirin to Merck's Claritin allergy pills.
May 6, 2014
0
0
German pharmaceutical group Bayer has made a bid for its Norwegian partner and competitor Algeta, specialised in cancer treatments, for 1.8 billion euro ($2.4 billion), the Nordic company said Tuesday.
Nov 26, 2013
0
0
